CALX

Calix is mid-recovery, not broken. FY2025 revenue rebounded to $1.00B (+20.3%) after an ugly 18% drop in FY2024, gross margin is a healthy 56.8%, and operating cash flow nearly doubled to $135M against just $19.4M of capex — so real free cash flow is roughly $116M, a ~5% yield on the $2.37B cap. The balance sheet is a genuine asset: liabilities/equity of only 0.23x, cash up 231% to $143M, and per the 10-K MD&A $388.1M of cash plus marketable securities with effectively no debt. Management is voting with the checkbook — $93.6M repurchased in FY2025 (up 776%), a fresh $125M authorization in January 2026, and $148.7M already bought back in 2026 to date — shrinking the 65.6M share count and signaling they view the stock as cheap.

The problem is that GAAP profitability remains thin and the headline price already discounts a recovery that has only partly arrived. Operating margin is just 2.1% and ROE 2.1%; the 138.7x trailing P/E and 2.4x sales bake in substantial future margin expansion. The earnings 'history' is misleading — FY2021's $238M net income sits against a still-negative -$372M accumulated deficit, so it was almost certainly a one-time tax item, not operating strength, and the company actually lost $29.7M in FY2024. R&D of $190M (19% of revenue) keeps GAAP earnings suppressed even as cash generation is solid.